Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)

被引:23
作者
CastriotaScanderbeg, A [1 ]
Sacco, M [1 ]
机构
[1] SCI INST CASA SOLLIEVO SOFFERENZA,DEPT PAEDIAT,SAN GIOVANNI ROTO,ITALY
关键词
thalassaemia major; L1 (deferiprone); immune function; vasculitis;
D O I
10.1046/j.1365-2141.1997.d01-2014.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function, including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.
引用
收藏
页码:254 / 255
页数:2
相关论文
共 7 条
[1]  
ALREFAIE FN, 1993, ACTA HAEMATOL-BASEL, V89, P86
[2]   RESULTS OF LONG-TERM DEFERIPRONE (L1) THERAPY - A REPORT BY THE INTERNATIONAL STUDY-GROUP ON ORAL IRON CHELATORS [J].
ALREFAIE, FN ;
HERSHKO, C ;
HOFFBRAND, AV ;
KOSARYAN, M ;
OLIVIERI, NF ;
TONDURY, P ;
WONKE, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (01) :224-229
[3]   ARTHROPATHY IN THALASSEMIA PATIENTS RECEIVING DEFERIPRONE [J].
BERKOVITCH, M ;
LAXER, RM ;
INMAN, R ;
KOREN, G ;
PRITZKER, KPH ;
FRITZLER, MJ ;
OLIVIERI, NF .
LANCET, 1994, 343 (8911) :1471-1472
[4]  
HOFFBRAND AV, 1989, LANCET, V2, P457
[5]  
Hoffbrand AV, 1996, SEMIN HEMATOL, V33, P1
[6]  
KONTOGHIORGHES GJ, 1987, LANCET, V1, P1294
[7]   FATAL SYSTEMIC LUPUS-ERYTHEMATOSUS IN PATIENT TAKING ORAL IRON CHELATOR-L1 [J].
MEHTA, J ;
SINGHAL, S ;
REVANKAR, R ;
WALVALKAR, A ;
CHABLANI, A ;
MEHTA, BC .
LANCET, 1991, 337 (8736) :298-298